While fusion proteins of the extracellular parts of receptor subunits termed cytokine traps turned out to be promising cytokine inhibitors for anti-cytokine therapies their mode of action has not been analyzed. We developed a fusion protein consisting of the ligand binding domains of the IL-6 receptor subunits IL-6Rα and gp130 that acts as a highly potent IL-6 inhibitor. Gp130 is a shared cytokine receptor also used by the IL-6-related cytokines oncostatin M (OSM 1 ) and leukemia inhibitory factor (LIF). In this study we show that the IL-6 receptor fusion protein (IL-6-RFP) is a specific IL-6 inhibitor that does not block OSM or LIF. We characterized the complex of IL-6-RFP and fluorescently labelled IL-6 (YFP-IL-6) by blue-native PAGE and gel filtration. A two-fold molar excess of IL-6-RFP over IL-6 is sufficient to entirely bind IL-6 in a complex with IL-6-RFP. As shown by treatment with urea and binding competition experiments, the complex of IL-6 and IL-6-RFP is more stable than the complex of IL-6, soluble IL-6Rα and soluble gp130. By live cell imaging we demonstrate that YFP-IL-6 bound to the surface of cells expressing gp130-CFP is removed from the plasma membrane upon addition of IL-6-RFP. The apparent molecular mass of the IL-6/IL-6-RFP complex determined by blue-native PAGE and gel filtration suggests that IL-6 is trapped in a structure analogous to the native hexameric IL-6 receptor complex. Thus, fusion of the ligand binding domains of heteromeric receptors leads to highly specific cytokine inhibitors with superior activity compared to the separate soluble receptors.
Cytokines are important mediators in the regulation of immune responses and inflammation. Dysregulated cytokine signaling leads to chronic inflammation and cancer. Therefore, pro-inflammatory cytokines such as tumor necrosis factor (TNF), interleukin-1 and interleukin-6 have been identified as promising therapeutic targets. First approaches to specifically block the action of pro-inflammatory cytokines have focussed on the use of neutralizing antibodies against a specific cytokine or its receptor. Only recently, the value of soluble cytokine receptors as cytokine antagonists for the treatment of inflammatory diseases has been fully recognized. Pro-inflammatory cytokines signal through receptor proteins consisting of an extracellular part, a single transmembrane region and a cytoplasmic domain. Ligand-binding to the extracellular part of the receptor results in the activation of signal transduction cascades by the cytoplasmic domain. Soluble receptors consisting only of the extracellular part are potent inhibitors of cytokine activity. They bind the cytokine with the same specificity and affinity as the membranebound receptors without eliciting an intracellular signal. A dimeric form of the soluble TNFreceptor is currently used for the treatment of inflammatory diseases caused by elevated TNF expression (1) . Most cytokines signal through heteromeric receptor complexes consisting of two or more different receptor subunits. In such a case inhibition of cytokine activity by soluble receptors is more challenging. Recently, we and others have shown that the appropriate fusion of different soluble receptor proteins results in highly potent antagonists (2, 3) . Interleukin-6 (IL-6) has been validated as a target for the treatment of several diseases such as rheumatoid arthritis and the lymphoproliferative disorder known as Castleman's disease (4, 5) . IL-6 signals through two different receptor proteins. It first binds to an α-receptor subunit (IL-6Rα). The low-affinity complex of IL-6 and IL-6Rα engages the signal transducing receptor subunit gp130 leading to a high-affinity receptor complex and the initiation of the cytoplasmic signaling cascades.
Upon ligand binding Janus tyrosine kinases (Jaks) that are constitutively associated with gp130 become activated resulting in tyrosine phosphorylation of the transcription factor STAT3 (signal transducer and activator of transcription 3). Activated STAT3 accumulates in the nucleus where it induces IL-6 target genes (6) . While soluble gp130 (sgp130) has a moderate antagonistic effect on IL-6 activity (7), soluble IL-6Rα (sIL-6Rα) acts even agonistically (8) .
Together with IL-6, sIL-6Rα can be regarded as a co-ligand required for the activation of gp130. We have shown that in the presence of sgp130 the agonistic activity of sIL-6Rα is converted to an antagonistic activity (9) . Thus, the combined application of sIL-6Rα and sgp130 results in a strong inhibition of IL-6 activity. The extracellular part of gp130 consists of a single Ig-like domain (D1) followed by five fibronectin type III-like domains (D2-D6) (10) . Domains D2 and D3 form the cytokine binding module (CBM) which is the structural hallmark of the hematopoietic cytokine receptors (11) . The extracellular part of IL-6Rα also consists of an Iglike domain (D1) followed by a CBM (D2 and D3) (12) . By mutational analysis it was shown that IL-6 contacts its receptors with three distinct binding sites (13) . Site I binds the CBM of IL-6Rα (14) , sites II and III interact with the CBM and D1 of gp130, respectively (15) . Recently, the structure of the soluble hexameric IL-6 receptor complex consisting of two molecules of each IL-6, sIL-6Rα and sgp130 (D1-D3) has been solved by X-ray crystallography (16) . One IL-6 molecule contacts with its site II the CBM of one gp130 and with its site III the Iglike domain of a second gp130 molecule. The same is valid for the second IL-6 molecule leading to a highly symmetric complex. Based on the structural features of the IL-6 receptor complex and the well characterized antagonistic activity of the combination of sIL-6Rα and sgp130, we designed a fusion protein (interleukin-6 receptor fusion protein, IL-6-RFP) consisting of the ligand binding domains of gp130 (D1-D3) and IL-6Rα (D2-D3) fused with an appropriate peptide linker ( fig. 7A) (3) . We have shown that this fusion protein acts as a highly potent IL-6 inhibitor. The cytokine receptor gp130 is a shared receptor subunit that is used by other IL-6-type cytokines such as interleukin-11 (IL-11), oncostatin M (OSM) and leukemia inhibitory factor (LIF) (17, 18) . While IL-6-RFP does not inhibit IL-11 (3) its activity towards LIF and OSM has not been tested yet.
While the importance of fused cytokine receptors as future drugs has been recognized (19) their mode of action has not been analyzed in sufficient detail. Therefore, we investigated the specificity, stability and stoichiometry of the complex formed by IL-6 and IL-6-RFP. We show that IL-6-RFP is a highly specific IL-6 inhibitor that does not interfere with the bioactivity of the related cytokines LIF and OSM. A new method for the analysis of protein-protein interactions based on blue-native gel electrophoresis, fluorescent fusion proteins and fluorescence-scanning is presented. We show that a two-fold molar excess of IL-6-RFP over IL-6 is sufficient to completely trap IL-6 in a binary IL-6/IL-6-RFP complex. The complex of IL-6/IL-6-RFP is more stable than the complex of IL-6 with the separate soluble receptors sIL-6Rα and sgp130. As shown in a live cell imaging experiment YFP-IL-6 once bound to its cell surface receptors is removed from the plasma membrane upon addition of IL-6-RFP. Analysis of the stoichiometry by native gel electrophoresis and gel filtration suggests that the architecture of the IL-6/IL-6-RFP complex is analogous to the hexameric receptor complex identified by X-ray crystallography. Thus, IL-6-RFP is a promising IL-6 inhibitor for the treatment of diseases caused by dysregulated IL-6 expression.
EXPERIMENTAL PROCEDURES
Cytokines, cytokine receptors. Recombinant human IL-6 was expressed in Escherichia coli, refolded and purified as described (20) . The specific activity of IL-6 was measured by a B9 cell proliferation assay (21) . Oncostatin M (OSM) was purchased from PeproTech (Rocky Hill, NJ) and leukemia inhibitory factor (LIF) from Chemicon International (Temecula, CA). sIL-6Rα was expressed in insect cells as previously described (22 Reporter gene assay. HepG2 cells were seeded onto 6-well plates (9.6 cm 2 /well) and transiently cotransfected with pGL3-α2M-Luc (construct with luciferase gene regulated by the α2-macroglobulin promoter) and pCR TM 3 LacZ (galactosidase construct with a constitutively active promoter), (Amersham Biosciences, Piscataway, NJ). Cells were starved in serum-free medium for 6 h and subsequently stimulated with 5 ng/ml IL-6 or the combination of IL-6 and IL-6-RFP for 16 h at molar ratios indicated. In order to determine the specificity of IL-6-RFP, HepG2 cells were stimulated in parallel with 0.5 ng/ml OSM or a mixture of OSM and IL-6-RFP, or with 5 ng/ml LIF or a mixture of LIF and IL-6-RFP. Previous to stimulation, the corresponding cytokine and IL-6-RFP were incubated for 30 min at 37°C to allow complex formation. Preparation of cellular lysates and luciferase measurements were carried out according to the instructions of the manufacturer (Promega, Madison, WI). The luciferase activity values were normalized to the transfection efficiency which was determined as β-galactosidase activity. The experiments were carried out in triplicates and the mean values and standard deviations were calculated. Preparation of cell lysates, SDS-PAGE, Western blotting and immunodetection. HepG2 cells were cultured on 6-well plates, starved overnight and stimulated with the indicated cytokine or combination of cytokine and IL-6-RFP for 20 min. Subsequently cells were lysed with RIPA (radioimmune precipitation assay) lysis buffer (50 mM tris-HCl, pH 7.4, 150 mM NaCl, 1 mM EDTA, 0.5% Nonidet P-40, 1 mM NaF, 15% gycerol, 20 mM β-gycerophosphate, 1 mM Na 3 VO 4 , 0.25 mM phenylmethylsulfonyl fluoride, 5 μg/ml aprotinin and 1 μg/ml leupeptin). The lysates were analyzed with SDS-PAGE, Western blotting and immunodetection using an antibody directed against phospho-tyrosine(705)-STAT3 (Cell Signaling, Danvers, MA) or STAT3 (type H190, Santa Cruz Biotechnology, Santa Cruz, CA). Both antibodies were used in a 1:1,000 dilution in TBS-N (20 mM tris-HCl, pH 7.6, 137 mM NaCl and 0.1% Nonidet P-40). Purification and expression of YFP-IL-6 in insect cells. High five (H5) insect cells (Invitrogen) were cultured at 27°C in Sf-900II medium (Gibco) containing 2 μg/ml blasticidine. In order to stably transfect the cells with an expression plasmid coding for YFP-IL-6, the Cellfectin method (Invitrogen) was used. 72 hours after seeding of the stably transfected cells, the supernatants were harvested and subseqently cell debries was removed by centrifugation and sterile filtration. YFP-IL-6 was purified from cell supernatants by affinity chromatography using immobilized sIL-6Rα. The eluates were supplemented with 0.02% bovine serum albumin (BSA) in order to increase protein stability, and dialyzed overnight against phosphate-buffered saline (0.2 M NaCl, 2.5 mM KCl, 8 mM Na 2 HPO 4 , 1.5 mM KH 2 PO 4 ). The concentration of YFP-IL-6 in the eluted factions was determined by SDS-PAGE, Western blotting, ELISA (23) and fluorescence spectroscopy. Fluorescence spectroscopy. Samples containing YFP-IL-6 were excited at a wavelengh of 514 nm, while the light emission between 520 and 600 nm was detected. The emission maximum of YFP at 525 nm was used for determination of the YFP-IL-6 concentration. Expression of IL-6-RFP in baculovirus-infected insect cells. IL-6-RFP was cloned as described (3) . The linker that joins D1-D3 of human gp130 with D2-D3 of human IL-6Rα consists of the flexible extracellular "stalk" region of IL-6Rα (Ala 323 -Val 362 ) and is therefore supposed to be of low antigenicity. An additional N-glycosylation site is introduced with the linker (Asn-Ala-Thr) (3). To produce IL-6-RFP using the baculovirus expression system the instructions given by the "Baculovirus expression vector system manual" (BD Biosciences Pharmingen TM , San Diego, CA) were followed. The DNA encoding IL-6-RFP was cut out from the vector pSVL-IL-6-RFP by XbaI and BamHI (Roche Applied Science) and inserted into the polyhedrin locus-based baculovirus transfer vector pVL1392 digested with the same enzymes. Sf21 insect cells were cultivated at 27°C in Sf-900II medium with 10% FCS. Cells were cotransfected with 4 μg pVL1392-IL-6-RFP plasmid and 0.5 μg BaculoGold TM DNA. Single virus clones were obtained from the cell supernatants by end point dilution. Several clones were screened for expression of IL-6-RFP in Sf21 cells by ELISA. The selected virus clone was then amplified by infecting Sf158 cells cultivated at 27°C in serum-free Sf-900II medium. For protein expression, exponentially growing Sf158 cells were infected with the recombinant IL-6-RFP baculovirus. Three days after infection the cell supernatant containing IL-6-RFP (about 1 µg/ml) was harvested and cleaned from cells and cellular debris by centrifugation and sterile filtration. Purification of IL-6-RFP by affinity chromatography. IL-6-RFP was purified from Sf158 supernatants by affinity chromatography with IL-6 immobilized to CNBr-Sepharose (Amersham Biosciences). After applying the cell supernatants to the column and washing with phosphate-buffered saline containing 0.05% Tween 20, proteins were eluted with 1 M acetic acid and subsequently neutralized by 2 M TrisHCl (pH 9). Fractions collected during affinity chromatography were analyzed by SDS-PAGE, silver-staining, Western blotting and immunodetection with antibodies directed against sIL-6Rα or FLAG (Sigma, Munich, Germany). The eluates were supplemented with 0.02% BSA (200 µg/ml) and dialyzed overnight against phosphate-buffered saline. The final concentration of purified IL-6-RFP was about 10 µg/ml at a yield of about 70%. IL-6-RFP was stored for up to three years at -20°C without major loss of activity. Quantification of IL-6-RFP by ELISA. An ELISA for the quantification of FLAG-tagged IL-6-RFP was carried out as described (9) . The ELISA plates were coated with 0.3 μg/ml of FLAG monoclonal antibody (Sigma), and 50 ng/ml of biotinylated monoclonal antibody B-T2 (Diaclone, Besançon, France) was used as secondary antibody. The standard curve was obtained by two-fold serial dilutions of sgp130-FLAG expressed in COS-7 cells and calibrated by sgp130 ELISA (9) . Blue-native page and detection of YFP fluorescence. To allow complex formation, YFP-IL-6 and IL-6-RFP (or YFP-IL-6, sIL-6Rα and sgp130) were incubated for 30 min at room temperature at molar ratios as indicated. Complexes were separated by blue-native page (24,25) using gradient polyacrylamide gels (from 4% to 12% or 4% to 20% polyacrylamide). The cathode buffer was composed of 50 mM tricine, 15 mM bistris and 0.002% Coomassie Brilliant Blue ® G 250 (Serva, Heidelberg, Germany), while the anode buffer contained 50 mM bistris/HCl, pH 7. Bovine serum albumin (BSA) was used as molecular weight marker protein. In addition BSA was utilized as an internal marker protein, since YFP-IL-6 and IL-6-RFP were supplemented with BSA in order to increase protein stability. The fluorescence of YFP was detected with a Typhoon gel imager (Amersham Biosciences) using an excitation at 488 nm, while the emission was detected using a 500-540 nm bandpass filter. After detection the gels were fixed and silver-stained. Live cell imaging by confocal laser-scanning microscopy. Confocal microscopy of living cells was carried out using a Zeiss LSM 510 Meta confocal laser-scanning microscope (Zeiss, Jena, Germany) equipped with an argon-laser, a 63x/1.2N water-corrected objective, an open cell cultivation chamber (Pecon, Erbach, Germany) and a CO 2 -incubation and heating unit (Zeiss). For live cell imaging COS-7 cells were transfected with pSVL-gp130id-CFP coding for an internalization-deficient mutant of gp130 fused to CFP (26) . Subsequently cells were seeded onto 42 mm glass coverslips and 48 hours after transfection, coverslips were placed into an open cell cultivation chamber. The CO 2 -incubation and heating unit maintained a constant CO 2 -amount of 5% and a temperature of 37°C. For recording of multiple fluorescence signals from one cell the multi-track function of the LSM 510 Meta was used. Cyan fluorescence was excited with λ = 458 nm (5% transmission) and detected after a bandpass filter BP 480/20. Yellow fluorescence was excited with λ = 514 nm (5% transmission) and a bandpass filter BP 530-600 was used. All images represent confocal slices of about 1 μm. Cells were costimulated with 240 ng/ml YFP-IL-6 and 3 μg/ml sIL-6Rα and CFP-and YFPfluorescence was measured every 4 min over one hour. In a second approach a 10-fold molar excess of IL-6-RFP over YFP-IL-6 was added to the cells 21 min after costimulation. Gel filtration. Gel filtration was carried out at 4°C with a Superdex 200 16/60 column (Amersham Biosciences) at a flow rate of 1 ml/min. During each run, the light absorption at 280 nm was measured. The column was calibrated with 9 mg of a gel filtration standard protein mixture containing thyroglobulin, 670 kD; γ-globulin, 158 kD; ovalbumin, 44 kD; myoglobin, 17 kD and vitamin B 12 , 1.35 kD (BioRad, Hercules, CA). During gel filtration of YFP-IL-6 and the YFP-IL-6/IL-6-RFP complex 3 ml-fractions were collected.
RESULTS

IL-6-RFP inhibits acute phase protein gene induction and STAT3 activation by IL-6 but not by the related cytokines OSM and LIF.
Human hepatocellular carcinoma cells (HepG2) respond to IL-6, OSM and LIF stimulation with the induction of acute phase protein genes (27) and are therefore well suited to test the specificity of IL-6-RFP. As shown in fig. 1A , IL-6-RFP concentration-dependently inhibits the induction of the α2-macrogloblulin (α2M) promoter by IL-6 in a reporter gene assay. Already a two-fold molar excess of IL-6-RFP over IL-6 leads to a reduction of the biological response of about 70%. A more than ten-fold molar excess suppresses gene induction to nearly basal levels. At concentrations of IL-6-RFP that completely inhibit IL-6 activity, gene induction by OSM is not disturbed (fig. 1B) . At a 30-fold molar excess of IL-6-RFP over LIF, LIF activity is not affected. A moderate inhibiton of LIF activity is observed at a 60-fold excess. Fig. 1 C shows that IL-6-RFP acts on IL-6-mediated reporter gene induction not only after preincubation of the cytokine and the inhibitor (procedure a) but also when the inhibitor is given simultaneously (b, c) or with a delay of 10 min (d) or 20 min (e). While reporter gene induction is measured 16 h after cytokine stimulation, STAT3 tyrosine phosphorylation can be detected within minutes ( fig. 1D ). STAT3 activation is inhibited when IL-6 and IL-6-RFP are preincubated for 30 min (procedure a) or added simultaneously (c). In this short-term assay, a delay of the action of IL-6-RFP is not tolerated (d, e). IL-6-RFP does not interfere with STAT3 activation induced by LIF or OSM (Fig. 1E) . Analysis of the interaction between IL-6 and IL-6-RFP by a fluorescence gel-shift assay. While the bioactivity of IL-6-RFP has been analyzed in detail ( fig. 1 and (3) ), the complex formation of IL-6-RFP and IL-6 has not been studied. In a recent publication we showed that fusion of the yellow fluorescent protein (YFP) to the Nterminus of IL-6 does not affect its bioactivity (26) . The fluorescent cytokine YFP-IL-6 was expressed in insect cells and purified by affinity chromatography. For stabilization of diluted solutions of YFP-IL-6, bovine serum albumin (BSA) was added. Different amounts of YFP-IL-6/BSA were loaded onto a non-denaturing polyacrylamide gradient gel and electrophoresis was performed under blue-native PAGE conditions. When the wet gel was analyzed by a fluorescence scanner, YFP-IL-6 was readily detectable as two separate bands ( fig. 2A, upper  panel, lanes 2 and 3) . Subsequently, the same gel was silver-stained ( fig.  2A, lower panel) . At the higher concentration (120 ng) the upper YFP-IL-6 band is clearly visible (filled triangle, lane 2), whereas the lower one is only weakly stained (open triangle, lane 2). At the lower concentration (24 ng, lane 3), YFP-IL-6 is hardly visible. Thus, the sensitivity of the fluorescence detection is similar or even exceeds the sensitivity of a silver stain. In lane 1, albumin alone was loaded onto the gel. The albumin monomer (65 kD) is the strongest band, but the dimer (130 kD), trimer (195 kD) and tetramer (260 kD) are also clearly detectable. These bands serve as molecular mass markers. The calculated molecular mass of YFP-IL-6 is 46 kD. Therefore, the band between the albumin dimer (130 kD) and the albumin monomer (65 kD) corresponds to a dimer of YFP-IL-6 (92 kD) while the lower band represents the monomer (46 kD). Addition of IL-6-RFP to YFP-IL-6 results in a marked shift of the fluorescent band which indicates complex formation of YFP-IL-6 with IL-6-RFP ( fig. 2A, lanes 4-6) . We often observed that the band-shift is accompanied with a considerable increase in fluorescence intensity. We attribute this phenomenon to quenching or dequenching of the fluorescence dependent on varying local concentrations of Coomassie, salts and polyacrylamide in the gradient gel. A two-fold molar excess of IL-6-RFP is sufficient to trap YFP-IL-6 completely (lane 4). Still at a 0.4-or 0.08-fold molar ratio of IL-6-RFP over YFP-IL-6 a complex is formed. To achieve a complex formation between sIL-6Rα and YFP-IL-6, a tenfold molar excess of sIL-6Rα is required (Fig. 2B,  lane 8) . The complex already disappears at a twofold molar excess (lane 9, compare to lane 4). The combination of sIL-6Rα and sgp130 (Fig. 2C ) requires a ten-fold molar excess to completely bind YFP-IL-6 while a two-fold molar excess leads to only a partial trapping of YFP-IL-6 (compare to lane 4, Fig. 2A ) These results indicate that IL-6-RFP binds YFP-IL-6 more efficiently than its soluble receptors. IL-6 forms a more stable complex with IL-6-RFP than with its soluble receptors. Three experiments were performed to assess the stability of the complexes formed by IL-6 and IL-6-RFP or IL-6 and its soluble receptors. In a first experiment, the complexes were incubated in the presence of urea at increasing concentrations. While the complex of IL-6/IL-6-RFP is still detectable in the presence of 6 M urea (Fig. 3A, filled triangle) , only a faint band of the IL-6/sIL-6Rα/sgp130 complex is visible in the presence of 2 M urea (Fig. 3B , filled triangle) that disappears at a concentration of 4 M urea. Interestingly, with increasing concentrations of urea the band of the YFP-IL-6 monomer becomes more intense (figs. 3A and 3B) suggesting that urea induces a dissociation of the YFP-IL-6 dimers into monomers. In a second approach, the complexes formed by YFP-IL-6 and IL-6-RFP or YFP-IL-6 and its soluble receptors were incubated with varying amounts of unlabelled IL-6 for two hours to determine the replacement of YFP-IL-6 by IL-6. A ten-fold molar excess of IL-6 over YFP-IL-6 is required to detect a replacement of YFP-IL-6 in the complex of YFP-IL-6 and IL-6-RFP (Fig. 4A) . The fluorescence intensity of the complex decreases at a ten-fold molar excess of IL-6 over YFP-IL-6 (filled triangle), while the fluorescence of the YFP dimer becomes more intense (open triangle). In case of the receptor complex formed by YFP-IL-6 and its soluble receptors lower amounts of unlabelled IL-6 are sufficient to displace YFP-IL-6 (Fig. 4B) . The fluorescence of the YFP-IL-6 dimer increases already, if IL-6 is added at a 0.1-fold molar ratio (open triangle). In a complementary third approach increasing amounts of sIL-6Rα and sgp130 were added to the complex formed by YFP-IL-6 and IL-6-RFP (Fig.  4C) . Hardly any YFP-IL-6/sIL-6Rα/sgp130 ternary complex is detectable after 2h. Conversely, when IL-6-RFP is added to a preformed YFP-IL-6/sIL-6Rα/sgp130 ternary complex, the complex of YFP-IL-6/IL-6-RFP is formed within 2 h already at an only 0.1-fold molar concentration of IL-6-RFP over sIL-6Rα and sgp130 (Fig. 4D) . Thus, the cytokine is more efficiently trapped in complex with IL-6-RFP than in complex with the soluble receptors. IL-6-RFP removes YFP-IL-6 from the cell surface receptor complex. Next we asked whether IL-6-RFP as a result of its superior activity is able to remove IL-6 from its receptor on the plasma membrane. Therefore, we transfected COS-7 cells with an internalization deficient (id) mutant of gp130 fused to CFP (gp130id-CFP (26)) and analyzed living cells by confocal laser-scanning microscopy. As shown in Fig. 5A , besides ER and Golgi-apparatus the plasma membrane of transfected cells is clearly visible in the CFP channel resulting from surface expression of gp130id-CFP. After addition of YFP-IL-6 and sIL-6Rα (COS-7 cells lack endogenous IL-6Rα) the fluorescent cytokine accumulates at the cell surface resulting in a membrane staining detected in the YFP channel. The intensities of YFP and CFP fluorescence in the regions of interest (ROIs) at the plasma membrane (red rectangles in Fig.  5A ) are depicted in Fig. 5B . YFP-IL-6 binding to gp130id-CFP reaches saturation within 50 minutes ( fig 5B, left diagram) .
In a second experiment (Fig. 5A, right panel) Within 25 minutes the IL-6 occupied receptors decrease by 50%. Thus, IL-6-RFP has the capacity to eliminate IL-6 from activated receptor complexes at the cell surface.
Determination of the molecular mass of the YFP-IL-6/IL-6-RFP complex by gel filtration. IL-6-RFP
was purified from insect cell supernatants by affinity chromatography on IL-6-Sepharose (Fig.  6A) . In non-reducing SDS-PAGE IL-6-RFP appears as a monomeric protein with an apparent molecular mass of about 80 kD (Fig. 6A, lane 2) . We used a calibrated gel filtration column to determine the molecular masses of YFP-IL-6, IL-6-RFP and the complex of YFP-IL-6 and IL-6-RFP. YFP-IL-6 was detected by fluorescence spectroscopic analysis of the collected fractions. IL-6-RFP was quantified by ELISA (3). YFP-IL-6 alone eluted in two peaks from the gel filtration column (Fig. 6B) . According to the retention times, these peaks correspond to YFP-IL-6 monomers (47 kD) and YFP-IL-6 dimers (94 kD). This finding is in line with the two species detected by blue-native PAGE. The elution profile of IL-6-RFP is shown in Fig.  6C . Interestingly, no monomeric IL-6-RFP could be detected. The major portion of IL-6-RFP is found in a peak corresponding to 170 kD that most probably represents the IL-6-RFP dimer. Also some higher molecular mass species were detected. Pre-incubation of YFP-IL-6 with a two-fold molar excess of IL-6-RFP resulted in a dramatic change in the elution patterns (Fig. 6D) . The whole population of YFP-IL-6 eluted earlier from the column corresponding to a higher apparent molecular mass. This finding indicates that YFP-IL-6 is completely trapped in a complex with IL-6-RFP confirming the results obtained by bluenative PAGE. Relevant fractions were analyzed by ELISA to detect IL-6-RFP (Fig. 6D, blue line) . All fractions that contain the shifted YFP-IL-6 also contain IL-6-RFP. In addition, a second peak of IL-6-RFP being devoid of YFP-IL-6 appears. This peak corresponds to the unliganded IL-6-RFP dimer. The apparent molecular mass of the YFP-IL-6/IL-6-RFP-complex derived from gel filtration (Fig.  6C) is 325 kD. If the complex is built up according to the native hexameric receptor complex (consisting of two molecules of each IL-6, IL-6Rα and gp130 (16)) a tetrameric complex is expected consisting of two molecules of YFP-IL-6 and two molecules of IL-6-RFP. The calculated molecular mass for such a complex is 264 kD. The discrepancy between the observed and calculated values can be attributed to the bulky architecture of the IL-6 receptor complex (16) as discussed below.
DISCUSSION
According to the X-ray structure of the soluble IL-6 receptor complex, IL-6 signals through a hexameric complex consisting of two molecules of each IL-6, IL-6Rα and gp130 (16) . The soluble receptors sIL-6Rα and sgp130 are present in human blood in considerable concentrations (50 ng/ml (28, 29) and 300 ng/ml (7,9), respectively. We found that the pairwise action of these soluble receptors blocks systemic IL-6 responses (9). Based on this observation we designed a fusion protein composed of the ligand binding domains of IL-6Rα (D2, D3) and gp130 (D1, D2, D3; Fig.  7A ) which turned out to be a highly potent inhibitor of IL-6 (3). Such novel cytokine inhibitors are promising candidates for future drugs against chronic inflammation and autoimmune diseases (19). Therefore, a characterization of their mode of action is of considerable importance. Since gp130 is the shared signaling receptor subunit of the IL-6-type cytokines, specificity of IL-6-RFP is a critical issue. On human cells, OSM signals through a heterodimer of gp130 and the OSM-receptor or a heterodimer of gp130 and the LIF-receptor (LIFR) (30) . Even a large excess of IL-6-RFP over OSM does not inhibit OSM activity (Fig. 1B and E) indicating that the affinity of OSM to the gp130 moiety of IL-6-RFP is very low. LIF signals through a heterodimer of gp130 and the LIFR (30) . At a 60-fold molar excess of IL-6-RFP over LIF, LIF-activity is moderately affected. This cross-reactivity of IL-6-RFP can be explained by low-affinity binding of LIF to domains D2 and D3 of gp130 (31) . However, at concentrations of IL-6-RFP sufficient to trap IL-6 in a high-affinity complex the fusion protein is a highly specific IL-6 inhibitor. The low activity of IL-6-RFP towards OSM and LIF is in line with the ineffective neutralization of these cytokines by the full-length soluble gp130 (D1-D6). A 300-fold molar excess of sgp130 over OSM resulted in only a marginal inhibition of OSM bioactivity (7) . Interestingly, in a long-term reporter gene assay that mimics IL-6 bioactivity a short delay of IL-6-RFP application is well tolerated (Fig. 1C) . To inhibit the early activation of STAT3 in response to IL-6, however, IL-6-RFP has to be added at least simultaneously (Fig. 1D) . These results show that a short initial pulse of STAT3 activation is not sufficient for a robust gene induction but that the cytokine has to act for a considerable period of time. This means for the treatment of a disease with IL-6-RFP that the inhibitor can block the biological activity of IL-6 even when applied after the cytokine release. This is further substantiated by the results of our live cell imaging experiment. IL-6 bound to the cell surface is removed from the receptor complex upon addition of IL-6-RFP (Fig.  5) . The shift of GFP fusion proteins in native gels can be used to detect protein-protein interactions (32) . We combined the application of blue-native gel electrophoresis, fluorescent fusion proteins and advanced fluorescence gel-imaging to analyze the interaction of IL-6-RFP with IL-6. YFP-IL-6 was generated by fusion of the yellow fluorescent protein (YFP) to the N-terminus of IL-6. The 28 N-terminal amino acids of IL-6 are not involved in receptor binding (33) . Therefore, fusion of YFP to the N-terminus of IL-6 does not affect IL-6 bioactivity (26) . Indeed, the interaction of YFP-IL-6 with IL-6-RFP could be visualized by a dramatic shift of the fluorescent band (Fig. 2) . Only a two-fold molar excess of IL-6-RFP over YFP-IL-6 is sufficient to completely trap YFP-IL-6 in a high molecular mass complex. In these fluorescence gel shift assays the separate soluble receptor proteins sIL-6Rα and sgp130 are of lower activity which is in line with their lower potential to inhibit IL-6 (3). The ranking of efficiency in trapping IL-6 is IL-6-RFP > sIL-6Rα/sgp130 > sIL-6Rα > sgp130. Sgp130 alone has no detectable affinity to IL-6 (not shown). The superior activity of IL-6-RFP is also reflected in the increased stability of the YFP-IL-6/IL-6-RFP complex towards denaturation by urea, the low rate of replacement of YFP-IL-6 by non-tagged IL-6, the resistance of the YFP-IL-6/IL-6-RFP complex towards an excess of the soluble receptor proteins (figs. 3 and 4) and the elimination of receptor bound YFP-IL-6 from receptor complexes at the plasma membrane (Fig. 5) . In blue-native PAGE the mobility of the complex of YFP-IL-6 and IL-6-RFP is lower than the mobility of the albumin tetramer (260 kD, Fig.  2A) . From a plot of the logarithm of molecular masses of the BSA multimers versus the relative migration distances (R f, not shown) we calculated an apparent molecular mass of about 290 kD for the complex of YFP-IL-6 and IL-6-RFP. We performed gel filtration with a calibrated column (Fig. 6) to corroborate the molecular masses determined by blue-native PAGE. Gel filtration confirmed the observations made by blue-native PAGE. We found that preparations of YFP-IL-6 consist of a monomeric and a dimeric species (Fig.  6B) . Dimerization of YFP-IL-6 is not caused by the YFP-moiety since YFP appears as a monomer in native PAGE (not shown). Thus, dimerization of the fusion protein is attributed to the known property of recombinant IL-6 to form dimers. The meta-stable IL-6 dimer has been described to dissociate in the presence of urea with a midpoint of dissociation at 3 M urea (34) . The behaviour of YFP-IL-6 in our gel-shift assays is in agreement with the biophysical investigations on the IL-6 dimer. The mobility of the IL-6/IL-6-RFP complex does not change under conditions that lead to dissociation of the YFP-IL-6 dimer (Fig. 3) indicating that IL-6-RFP is largely complexed with monomeric YFP-IL-6. This observation is in line with the fact that IL-6 dimerizes by interactions of the gp130 binding sites of two IL-6 molecules (34). These sites are occupied upon binding of IL-6 to IL-6-RFP (Fig. 7C) . Unexpectedly, unliganded IL-6-RFP elutes from the gel filtration column with a retention time corresponding to a dimeric protein. Sgp130 as well as sIL-6Rα are monomeric proteins that interact in the presence of IL-6 (35). However, in the X-ray structure of the hexameric IL-6 receptor complex (16) four contacts between IL-6Rα and gp130 were identified. Possibly, in the dimeric IL-6-RFP these contacts are partially stabilized by the covalent linkage of the corresponding IL-6Rα and gp130α domains leading to the formation of an IL-6-RFP dimer in the absence of IL-6 (Fig. 7B) . If we assume a preformed IL-6-RFP dimer as depicted in Fig. 7B , IL-6 fits well into this assembly leading to a complex of IL-6 and IL-6-RFP built up in analogy to the hexameric IL-6 receptor complex (Fig. 7C) . The apparent molecular masses determined by gel filtration (325 kDa) and blue-native PAGE (290 kD) are higher than the calculated molecular mass (264 kD) of the (IL-6) 2 /(IL-6-RFP) 2 complex. However, the complex depicted in Fig. 7C is not a highly compact structure but rather extended comprising a real cavity between the two IL-6 molecules. This architecture might explain the increased apparent molecular mass. A similar deviation between calculated and apparent molecular masses has also been observed in analysis of the soluble IL-6 receptor complex by gel filtration and analytical ultracentrifugation (35) . Taken together our analysis by blue-native PAGE and gel filtration suggests that the IL-6/IL-6-RFP complex is built up in close analogy to the soluble extracellular hexameric IL-6 receptor complex. The latter complex is held together by ten proteinprotein interactions (twice sites I, IIa, IIb, IIIa and IIIb, Fig. 7C ). The superior stability of the IL-6/IL-6-RFP complex in comparison with a similar complex built up by IL-6, sIL-6Rα and sgp130 is caused by the stabilization of these interactions through a covalent linkage of the ligand binding domains of sIL-6Rα and sgp130. Thus, a molecular basis is provided for the high specificity and superior affinity of IL-6-RFP in comparison to other IL-6 inhibitors. Therefore, the fusion of ligand binding domains of heteromeric cytokine receptors is a promising approach for novel anticytokine therapies. FOOTNOTES * This work was supported by the Deutsche Forschungsgemeinschaft (Sonderforschungsbereich SFB 542 and Graduiertenkolleg "Biointerface" GRK 1035) and the Fonds der Chemischen Industrie (Frankfurt am Main). The authors would like to thank Dr. John Wijdenes (Diaclone, Besançon, France) for the kind gift of the gp130 antibody B-T2. We thank Dr. Rene Krieg for his help with the fluorescence scanner and Andrea Küster for excellent technical assistance. 1 The abbreviations used are: BSA, bovine serum albumin; CBM, cytokine binding module; CFP, cyan fluorescent protein; D, domain; IL, interleukin; Jak, Janus kinase; LIF, leukemia inhibitory factor; OSM, oncostatin M; PAGE, polyacrylamide gel electrophoresis; R, receptor; RFP, receptor fusion protein; ROI, region of interest; STAT, signal transducer and activator of transcription; TNF, tumor necrosis factor; YFP, yellow fluorescent protein FIGURE LEGENDS Fig. 1 : Bioactivity and specificity of IL-6-RFP (A) HepG2 cells were transfected with a reporter gene plasmid coding for luciferase under the control of the IL-6 responsive rat α2M-promoter. To investigate the concentration-dependence of inhibition of the IL-6 induced luciferase activity by IL-6-RFP, IL-6 and IL-6-RFP were incubated at the indicated molar ratios for 30 min at 37°C to allow complex formation. Subsequently HepG2 cells were stimulated for 16 h with the mixture of cytokine and inhibitor. Luciferase activity was measured in triplicates. (B) HepG2 cells were transfected as described in A and stimulated with IL-6, OSM or LIF. To investigate the specificity of the IL-6 inhibitor, IL-6, OSM or LIF were preincubated with IL-6-RFP for 30 min at 37°C at molar ratios indicated. Subsequently HepG2 cells were stimulated for 16 h with the mixture of cytokine and inhibitor and the luciferase activity induced upon α2M-promoter activation was measured. (C) HepG2 cells were transfected as described in A. IL-6 was incubated with a ten-fold molar excess of IL-6-RFP for 30 min at 37°C. Afterwards, HepG2 cells were stimulated for 16 h with the mixture of cytokine and inhibitor (procedure "a"). In "b" HepG2 cells were preincubated with IL-6-RFP for 30 min and then stimulated with IL-6 for 16 h, whereas in "c" IL-6 and IL-6-RFP were added simultaneously to the cells without preincubation. In "d" and "e" Hep G2 cells were stimulated with IL-6 for 10 or 20 minutes respectively, and subsequently treated with IL-6-RFP for 16 h. After that time luciferase activity induced upon α2M-promoter activation was measured. (D) Hep G2 cells were seeded onto 6-well plates and serum-starved overnight. Subsequently, IL-6 was incubated with a 5-fold molar surplus of IL-6-RFP at 37°C for 30 min to allow complex formation. The cells were stimulated with IL-6 or the mixture of IL-6 and IL-6-RFP for 20 min ("a"). In "c" IL-6 and IL-6-RFP were added simultaneously to the cells (without preincubation) for 20 min. In "d" and "e" Hep G2 cells were stimulated with IL-6 for 10 or 20 minutes, respectively, and afterwards treated with IL-6-RFP for 20 min. (E) OSM and IL-6-RFP or LIF and IL-6-RFP were preincubated for 30 min at 37°C at molar ratios indicated. Hep G2 cells were stimulated with OSM or LIF or a mixture of OSM and IL-6-RFP or LIF and IL-6-RFP for 20 min. After stimulation, HepG2 cells were lysed. The lysates were analyzed with SDS-PAGE, Western Blot and immunodetection with phospho-STAT3-or STAT3-specific antibodies. To compare the concentrations of IL-6-RFP (A), sIL-6Rα (B) or the combination of sIL-6Rα and sgp130 (C) sufficient to bind to YFP-IL-6, YFP-IL-6 was incubated with a 2-, 0.4-, 0.08-or 0.016-fold molar ratio of IL-6-RFP for 30 min at room temperature. In a parallel approach, YFP-IL-6 was mixed with a 10-, 2-, 0.4-, 0.08-or 0.016-fold molar ratio of sIL-6Rα or a 10-, 2-, 0.4-, 0.08-or 0.016-fold molar ratio of the combination of sIL-6Rα and sgp130 and also incubated for 30 min at room temperature. The protein complexes were separated by blue-native PAGE and the fluorescent YFP-IL-6 was visualized by fluorescence detection. Subsequently the polyacrylamide gels were fixed and silver-stained. To allow complex formation, 24 ng YFP-IL-6 were incubated with a two-fold molar surplus of IL-6-RFP (74 ng) for 30 min at room temperature (A). In a parallel approach (B), YFP-IL-6 (24 ng), sIL-6Rα (44 ng) and sgp130 (74 ng) were mixed at a molar ratio of 1:2:2 and also incubated at room temperature for 30 min to enable complex formation. Then the indicated amounts of urea were added and incubated for another 10 min at room temperature. After incubation, the protein complexes were separated by bluenative PAGE and the fluorescent YFP-IL-6 was visualized by fluorescence detection. Subsequently the polyacrylamide gel was fixed and silver-stained. Fig. 4 : Blue-native PAGE: competition of IL-6 with YFP-IL-6 trapped by IL-6-RFP or by sIL-6Rα and sgp130 (A) YFP-IL-6 was incubated with a two-fold molar surplus of IL-6-RFP for 30 min at room temperature to allow complex formation. In a parallel approach (B), YFP-IL-6 was mixed with a two-fold molar surplus of sIL-6Rα and sgp130. Subsequently, non-tagged IL-6 was added at increasing concentrations (0-, 0.1-, 1-, 10-and 100-fold molar ratio over YFP-IL-6) and incubated for two hours at room temperature. The protein complexes were separated by blue-native PAGE and the fluorescent YFP-IL-6 was visualized by fluorescence detection. The complexes YFP-IL-6/IL-6-RFP (C) and YFP-IL-6/sIL-6Rα/sgp130 (D) were preformed by incubation at 37°C for 30 min at molar ratios 1:2 (C) or 1:10:10 (D). Subsequently the complex YFP-IL-6/IL-6-RFP was incubated with a 0-, 0.1-, 1-and 10-fold molar excess of sIL-6Rα and sgp130 over IL-6-RFP for 2 h (C) and the complex YFP-IL-6/sIL-6Rα/sgp130 was incubated with a 0-, 0.1-, 1-fold molar ratio of IL-6-RFP over the soluble receptors for 2 h (D). 2) were separated by SDS-PAGE under non-reducing conditions. Subsequently the gel was silver-stained. M, marker proteins. (B) 57 μg YFP-IL-6 were analyzed on a calibrated Superdex 200 16/60 column (M w range 10-600 kD) at a flow rate of 1 ml/min. 3 ml fractions were collected and analyzed by fluorescence spectroscopy measuring theYFP emission at 525 nm. (C) IL-6-RFP (17.7 μg) was analyzed by gel filtration on the same column. 3 ml fractions were analyzed by ELISA (D) To enable complex formation, YFP-IL-6 (5.7 μg) was incubated with IL-6-RFP in a two-fold molar surplus (17.7 μg) for 30 min at room temperature. The complex was analyzed by gel filtration. The 3 ml fractions were analyzed by fluorescence spectroscopy to detect YFP-IL-6 and by an ELISA in order to determine the concentrations of IL-6-RFP. All molecular masses were calculated using a regression curve based on the separation of a known protein standard mixture. 
